A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.

Feng Wang,Jian Xiao,Yanqiao Zhang,Xianglin Yuan,Weijia Fang,Wei Wang,Xiaohua Hu,Zhixiang Zhuang,Fuxiang Zhou,Jieer Ying,Ying Yuan,Zengqing Guo,Xiang Yuan Wu,Qing-Feng Zou,Ming Ming He,Ying Guo,S Chen,Rui Hua Xu

A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.

2020

Feng Wang
Jian Xiao
Yanqiao Zhang
Xianglin Yuan
Weijia Fang
Wei Wang
Xiaohua Hu
Zhixiang Zhuang
Fuxiang Zhou
Jieer Ying
Ying Yuan
Zengqing Guo
Xiang Yuan Wu
Qing-Feng Zou
Ming Ming He
Ying Guo
S Chen
Rui Hua Xu

TPS4115Background: Previous studies showed that high dose vitamin C especially when administered intravenously might have anti-cancer effect. A recent preclinical study found that human colorectal ...

Keywords:

Medicine
advanced colorectal cancer
Internal medicine
Vitamin C
first line therapy
Bevacizumab
Oncology
FOLFOX
in patient

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations